These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 19108521)

  • 1. Review of patients with hepatosteatosis and chronic hepatitis C.
    Smoliński P; Pazgan-Simon M; Zuwała-Jagiełło J; Hałoń A; Rotter K; Gładysz A
    Przegl Epidemiol; 2008; 62(3):571-9. PubMed ID: 19108521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis.
    Petit JM; Benichou M; Duvillard L; Jooste V; Bour JB; Minello A; Verges B; Brun JM; Gambert P; Hillon P
    Am J Gastroenterol; 2003 May; 98(5):1150-4. PubMed ID: 12809841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection.
    Petta S; Cammà C; Di Marco V; Cabibi D; Ciminnisi S; Caldarella R; Licata A; Massenti MF; Marchesini G; Craxì A
    Antivir Ther; 2009; 14(5):631-9. PubMed ID: 19704165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucose intolerance and hypoadiponectinemia are already present in lean patients with chronic hepatitis C infected with genotype non-3 viruses.
    Anty R; Gelsi E; Giudicelli J; Mariné-Barjoan E; Gual P; Benzaken S; Saint-Paul MC; Sadoul JL; Huet PM; Tran A
    Eur J Gastroenterol Hepatol; 2007 Aug; 19(8):671-7. PubMed ID: 17625437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy.
    Chehadeh W; Al-Nakib W
    J Med Virol; 2009 Apr; 81(4):610-8. PubMed ID: 19235842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic steatosis and fibrosis in chronic hepatitis C in Taiwan.
    Hsieh MH; Lee LP; Hsieh MY; Tsai KB; Huang JF; Hou NJ; Chen SC; Lin ZY; Hsieh MY; Wang LY; Dai CY; Chuang WL; Yu ML
    Jpn J Infect Dis; 2007 Nov; 60(6):377-81. PubMed ID: 18032828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of steatosis on insulin secretion in chronic hepatitis C patients.
    Narita R; Abe S; Tabaru A; Otsuki M
    Am J Gastroenterol; 2007 Oct; 102(10):2173-80. PubMed ID: 17680843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of steatosis and inflammation on liver fibrosis in chronic hepatitis C.
    Nieminen U; Arkkila PE; Kärkkäinen P; Färkkilä MA
    Liver Int; 2009 Feb; 29(2):153-8. PubMed ID: 18482270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection.
    Hsu CS; Liu CH; Liu CJ; Wang CC; Chen CL; Lai MY; Chen PJ; Chen DS; Kao JH
    Am J Gastroenterol; 2009 Mar; 104(3):598-604. PubMed ID: 19262519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Body composition and hepatic steatosis as precursors of fibrosis in chronic hepatitis C patients.
    Adinolfi LE; Utili R; Ruggiero G
    Hepatology; 1999 Dec; 30(6):1530-1. PubMed ID: 10610353
    [No Abstract]   [Full Text] [Related]  

  • 11. [Adiponectin and chronic viral hepatitis].
    Yin HZ; Cao ZC
    Zhonghua Gan Zang Bing Za Zhi; 2009 Dec; 17(12):955-7. PubMed ID: 20038346
    [No Abstract]   [Full Text] [Related]  

  • 12. Serum levels of adipokines in patients with chronic HCV infection: relationship with steatosis and fibrosis.
    Tiftikci A; Atug O; Yilmaz Y; Eren F; Ozdemir FT; Yapali S; Ozdogan O; Celikel CA; Imeryuz N; Tozun N
    Arch Med Res; 2009 May; 40(4):294-8. PubMed ID: 19608019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of serum HCV RNA titer by bezafibrate therapy in patients with chronic hepatitis C.
    Fujita N; Kaito M; Tanaka H; Horiike S; Adachi Y
    Am J Gastroenterol; 2004 Nov; 99(11):2280. PubMed ID: 15555013
    [No Abstract]   [Full Text] [Related]  

  • 14. Recurrent hepatitis C and non-alcoholic fatty liver disease in transplanted patients: a review.
    Testino G; Sumberaz A; Leone S; Borro P
    Minerva Med; 2013 Apr; 104(2):225-32. PubMed ID: 23514999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virological relapse in chronic hepatitis C.
    Poordad FF; Flamm SL
    Antivir Ther; 2009; 14(3):303-13. PubMed ID: 19474464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic steatosis in chronic hepatitis B: contributing factors and effect on fibrosis.
    Elloumi H; Hefaiedh R; Gargouri D; Chedly-Debbiche A; Khayat O; Bel Hadj N; Kharrat J; Ghorbel A
    Tunis Med; 2008 Nov; 86(11):1000-3. PubMed ID: 19213493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigating the concurrent presence of HCV in serum, oral fluid and urine samples from chronic HCV patients in Faisalabad, Pakistan.
    Shafique M; Ahmad N; Awan FR; Mustafa T; Ullah M; Qureshi JA
    Arch Virol; 2009; 154(9):1523-7. PubMed ID: 19669078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A link between leptin and steatosis in chronic hepatitis C? Time to weigh up the fats.
    Patel K; Muir A; McHutchison JG; Patton HM
    Am J Gastroenterol; 2003 May; 98(5):952-5. PubMed ID: 12809813
    [No Abstract]   [Full Text] [Related]  

  • 19. [Fibrosis in chronic hepatitis C infection: mechanisms and cofactors].
    Bedossa P
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B163-7. PubMed ID: 12180284
    [No Abstract]   [Full Text] [Related]  

  • 20. [Steatosis in chronic viral hepatitis C: frequency, risk factors and relationship with fibrosis].
    Karoui S; Taieb Jomni M; Bellil K; Haouet S; Boubaker J; Filali A
    Tunis Med; 2008 Jul; 86(7):670-5. PubMed ID: 19472729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.